Advertisement

Pituitary

, Volume 20, Issue 5, pp 509–514 | Cite as

Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience

  • Yukiko Odake
  • Hidenori FukuokaEmail author
  • Masaaki Yamamoto
  • Yoshifumi Arisaka
  • Junya Konishi
  • Kenichi Yoshida
  • Ryusaku Matsumoto
  • Hironori Bando
  • Kentaro Suda
  • Hitoshi Nishizawa
  • Genzo Iguchi
  • Shozo Yamada
  • Wataru Ogawa
  • Yutaka Takahashi
Article

Abstract

Purpose

Acromegaly is a disease associated with an increased risk for several kinds of neoplasms including colon and thyroid cancer. Although the association between acromegaly and pancreatic neoplasms has not been elucidated, it has recently been reported that GNAS gene mutations were found in 58% of intraductal papillary mucinous neoplasms (IPMNs), which are representative pancreatic cystic lesions, suggesting a link between IPMNs and acromegaly. To assess the prevalence of pancreatic cystic lesions in patients with acromegaly, we performed a retrospective cross-sectional single institute study.

Methods

Thirty consecutive acromegalic patients (20 females and 10 males; mean age, 60.9 ± 11.9 years) who underwent abdominal contrast-enhanced computed tomography or magnetic resonance imaging between 2007 and 2015 at Kobe University Hospital were recruited. We also analyzed the relationship between presence of pancreatic cystic lesions and somatic GNAS mutations in pituitary tumors.

Results

Seventeen of 30 (56.7%) patients studied had pancreatic cystic lesions. Nine of 17 patients (52.9%) were diagnosed with IPMNs based on imaging findings. These results suggest that the prevalence of IPMNs may be higher in acromegalic patients in acromegalic patients than historically observed in control patients (up to 13.5%). In patients with pancreatic cystic lesions, the mean patient age was higher and the duration of disease was longer than in those without pancreatic cystic lesions (67.0 ± 2.3 vs. 53.0 ± 2.7 years, p < 0.001, 15.5 ± 2.4 vs. 7.3 ± 2.8 years, p = 0.04). There were no differences in serum growth hormone levels or insulin-like growth factor standard deviation scores between these two groups (21.3 ± 6.4 vs. 23.0 ± 7.4 ng/ml, p = 0.86, 6.6 ± 0.5 vs. 8.0 ± 0.6, p = 0.70). Neither the presence of somatic GNAS mutation in a pituitary tumor nor low signal intensity of the tumor in T2 weighted magnetic resonance imaging was associated with the presence of pancreatic cystic lesions.

Conclusions

These data demonstrate that old or long-suffering patients with acromegaly have a higher prevalence of pancreatic cystic lesions. Moreover, the prevalence of pancreatic cystic lesions may be increased in acromegalic patients.

Keywords

Acromegaly Pancreatic cysts IPMN 

Notes

Acknowledgements

We are grateful to Ms. M. Kitamura and Ms. C. Ogata for providing excellent assistance. This work was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education Science, Culture, Sports, Science, and Technology (15K09432, 24790945, 23659477, and 23591354), Grants-in-Aid for Scientific Research (research on hypothalamic-hypophyseal disorders) from the Ministry of Health, Labor and Welfare of Japan, Novo Nordisk, the Daiichi-Sankyo Foundation of Life Science, the Foundation of Growth Science, and the Naito Foundation.

Supplementary material

11102_2017_810_MOESM1_ESM.docx (12 kb)
Supplementary material 1 (DOCX 12 KB)

References

  1. 1.
    Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Katznelson L, Laws ER Jr, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951CrossRefPubMedGoogle Scholar
  3. 3.
    Tirosh A, Shimon I (2017) Complications of acromegaly: thyroid and colon. Pituitary 20:70–75CrossRefPubMedGoogle Scholar
  4. 4.
    Landis CA, Masters SB, Spada A et al (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692–696CrossRefPubMedGoogle Scholar
  5. 5.
    Springer S, Wang Y, Dal Molin M et al (2015) A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 149:1501–1510CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bassi C, Sarr MG, Lillemoe KD et al (2008) Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg 12:645–650CrossRefPubMedGoogle Scholar
  7. 7.
    Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32CrossRefPubMedGoogle Scholar
  8. 8.
    Tanaka M (2015) International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas. Ann Transl Med 3:286PubMedPubMedCentralGoogle Scholar
  9. 9.
    Gaujoux S, Salenave S, Ronot M et al (2014) Hepatobiliary and pancreatic neoplasms in patients with McCune–Albright syndrome. J Clin Endocrinol Metab 99:E97–E101CrossRefPubMedGoogle Scholar
  10. 10.
    Katznelson L, Atkinson JL, Cook DM et al (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract 17(Suppl 4):1–44CrossRefPubMedGoogle Scholar
  11. 11.
    Hagiwara A, Inoue Y, Wakasa K et al (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228:533–538CrossRefPubMedGoogle Scholar
  12. 12.
    Isojima T, Shimatsu A, Yokoya S et al (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59:771–780CrossRefPubMedGoogle Scholar
  13. 13.
    de Jong K, Nio CY, Hermans JJ et al (2010) High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroentero Hepatol 8:806–811CrossRefGoogle Scholar
  14. 14.
    Ikeda M, Sato T, Morozumi A et al (1994) Morphologic changes in the pancreas detected by screening ultrasonography in a mass survey, with special reference to main duct dilatation, cyst formation, and calcification. Pancreas 9:508–512CrossRefPubMedGoogle Scholar
  15. 15.
    Lee KS, Sekhar A, Rofsky NM et al (2010) Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 105:2079–2084CrossRefPubMedGoogle Scholar
  16. 16.
    Laffan TA, Horton KM, Klein AP et al (2008) Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 191: 802–807.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cheng S, Gomez K, Serri O et al (2015) The role of diabetes in acromegaly associated neoplasia. PloS ONE 10:e0127276CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Colao A, Cuocolo A, Marzullo P et al (1999) Impact of patient’s age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 84:1518–1523PubMedGoogle Scholar
  19. 19.
    Vitale G, Pivonello R, Auriemma RS et al (2005) Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol 63:470–476CrossRefGoogle Scholar
  20. 20.
    Matsumoto R, Fukuoka H, Iguchi G et al (2015) Accelerated telomere shortening in acromegaly; IGF-I induces telomere shortening and cellular senescence. PloS ONE 10:e0140189CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Parker E, Newby LJ, Sharpe CC et al (2007) Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int 72:157–165CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yamamoto M, Matsumoto R, Fukuoka H et al (2016) Prevalence of simple renal cysts in acromegaly. Intern Med 55:1685–1690CrossRefPubMedGoogle Scholar
  23. 23.
    Tanaka M, Fernandez-del Castillo C et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12:183–197CrossRefPubMedGoogle Scholar
  24. 24.
    van Keimpema L, Nevens F, Vanslembrouck R et al (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137:1661–1668CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Yukiko Odake
    • 1
  • Hidenori Fukuoka
    • 2
    Email author
  • Masaaki Yamamoto
    • 1
  • Yoshifumi Arisaka
    • 3
  • Junya Konishi
    • 4
  • Kenichi Yoshida
    • 1
  • Ryusaku Matsumoto
    • 1
  • Hironori Bando
    • 1
  • Kentaro Suda
    • 1
  • Hitoshi Nishizawa
    • 2
  • Genzo Iguchi
    • 2
  • Shozo Yamada
    • 5
  • Wataru Ogawa
    • 1
  • Yutaka Takahashi
    • 1
  1. 1.Division of Diabetes and Endocrinology, Department of Internal MedicineKobe University Graduate School of MedicineKobeJapan
  2. 2.Division of Diabetes and EndocrinologyKobe University HospitalKobeJapan
  3. 3.Department of GastroenterologyKobe University Graduate School of MedicineKobeJapan
  4. 4.Department of Medical and Healthcare SystemsKobe University Graduate School of MedicineKobeJapan
  5. 5.Department of Hypothalamic and Pituitary SurgeryToranomon HospitalTokyoJapan

Personalised recommendations